MedTrace Logo

Clinical Trial to Evaluate the Drug Drug Interaction of CKD-501 and D308

NCT03616392 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2018-11-19

No results posted yet for this study

Summary

Phase 1 trial to evaluate the drug drug interaction of CKD-501 and D308

Conditions

  • Diabetes Mellitus, Type II

Interventions

DRUG

D308, CKD-501

1. D308 2. CKD-501: Lobeglitazone sulfate 0.5mg

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-07-25
Primary Completion
2018-09-17
Completion
2018-11-13

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03616392 on ClinicalTrials.gov